GlassScriptPhysician profile
Angela Kalia
NPI 1952922882
$1,470.75
in general payments reported to CMS, 2019-2025
21 companies · $652 in 2025
The $652 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $186 · 2024: $632 · 2025: $652.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,471.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,470.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $246.05 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $168.72 | 2024-2025 | |
| Pfizer INC. | $124.11 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $110.49 | 2023 | Xarelto |
| Lilly USA, LLC | $104.12 | 2024-2025 | Jardiance, Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $92.17 | 2024-2025 | Bexsero, Pediarix, Penmenvy |
| Exact Sciences Corporation | $88.02 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $83.72 | 2024-2025 | Otezla, Repatha, Otezla |
| Aimmune Therapeutics, INC. | $68.11 | 2024 | |
| Dexcom, INC. | $66.43 | 2023-2025 | Dexcom G6 Transmitter |
| Inspire Medical Systems, INC. | $42.39 | 2025 | Inspire |
| Novartis Pharmaceuticals Corporation | $41.49 | 2025 | |
| Janssen Biotech, INC. | $38.32 | 2024 | Stelara, Tremfya, Simponi |
| Vertex Pharmaceuticals Incorporated | $33.44 | 2025 | |
| Merck Sharp & Dohme LLC | $28.87 | 2024-2025 | Vaxelis, Vaxneuvance, Gardasil 9 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $28.59 | 2024 | Airsupra |
| Astellas Pharma US INC | $24.22 | 2025 | Veozah |
| Xeris Pharmaceuticals, INC. | $23.99 | 2025 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.92 | 2023 | Spiriva Respimat, Stiolto Respimat |
| Regeneron Healthcare Solutions, INC. | $21.13 | 2025 | Dupixent |
| Abbott Laboratories | $14.45 | 2025 | Freestyle Libre 3 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Kalia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.